X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs ABBOTT INDIA - Comparison Results

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES ABBOTT INDIA VENUS REMEDIES/
ABBOTT INDIA
 
P/E (TTM) x -4.1 39.7 - View Chart
P/BV x 0.2 10.2 1.5% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 VENUS REMEDIES   ABBOTT INDIA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
ABBOTT INDIA
Mar-18
VENUS REMEDIES/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs1266,110 2.1%   
Low Rs613,996 1.5%   
Sales per share (Unadj.) Rs301.81,552.2 19.4%  
Earnings per share (Unadj.) Rs-24.9188.8 -13.2%  
Cash flow per share (Unadj.) Rs2.5196.4 1.3%  
Dividends per share (Unadj.) Rs055.00 0.0%  
Dividend yield (eoy) %01.1 0.0%  
Book value per share (Unadj.) Rs293.3796.6 36.8%  
Shares outstanding (eoy) m12.3421.25 58.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.33.3 9.5%   
Avg P/E ratio x-3.826.8 -14.0%  
P/CF ratio (eoy) x36.725.7 142.8%  
Price / Book Value ratio x0.36.3 5.0%  
Dividend payout %029.1 0.0%   
Avg Mkt Cap Rs m1,154107,376 1.1%   
No. of employees `0000.93.3 27.8%   
Total wages/salary Rs m3933,937 10.0%   
Avg. sales/employee Rs Th4,026.19,929.3 40.5%   
Avg. wages/employee Rs Th425.01,185.1 35.9%   
Avg. net profit/employee Rs Th-331.81,207.7 -27.5%   
INCOME DATA
Net Sales Rs m3,72432,985 11.3%  
Other income Rs m231,170 1.9%   
Total revenues Rs m3,74734,155 11.0%   
Gross profit Rs m3955,245 7.5%  
Depreciation Rs m338162 209.0%   
Interest Rs m35438 927.5%   
Profit before tax Rs m-2756,215 -4.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m322,203 1.4%   
Profit after tax Rs m-3074,012 -7.6%  
Gross profit margin %10.615.9 66.7%  
Effective tax rate %-11.535.4 -32.4%   
Net profit margin %-8.212.2 -67.8%  
BALANCE SHEET DATA
Current assets Rs m2,63822,655 11.6%   
Current liabilities Rs m2,3056,681 34.5%   
Net working cap to sales %8.948.4 18.5%  
Current ratio x1.13.4 33.8%  
Inventory Days Days13565 209.1%  
Debtors Days Days4629 158.9%  
Net fixed assets Rs m4,871835 583.0%   
Share capital Rs m123213 58.1%   
"Free" reserves Rs m3,49616,715 20.9%   
Net worth Rs m3,61916,928 21.4%   
Long term debt Rs m1,3740-   
Total assets Rs m7,50924,162 31.1%  
Interest coverage x0.2163.7 0.1%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.51.4 36.3%   
Return on assets %0.616.8 3.8%  
Return on equity %-8.523.7 -35.8%  
Return on capital %1.636.9 4.3%  
Exports to sales %00-   
Imports to sales %13.90-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m517NA-   
Fx inflow Rs m0369 0.0%   
Fx outflow Rs m5173,807 13.6%   
Net fx Rs m-517-3,438 15.0%   
CASH FLOW
From Operations Rs m5141,527 33.7%  
From Investments Rs m-123-2,148 5.7%  
From Financial Activity Rs m-387-1,024 37.8%  
Net Cashflow Rs m4-1,646 -0.3%  

Share Holding

Indian Promoters % 32.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.2 7.9 2.3%  
FIIs % 0.6 0.1 580.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 17.1 388.3%  
Shareholders   20,121 18,270 110.1%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   TTK HEALTHCARE  ALEMBIC LTD  CIPLA  ELDER PHARMA  UNICHEM LAB  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Related Views on News

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY19); Net Profit Up 70.8% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, ABBOTT INDIA has posted a net profit of Rs 824 m (up 70.8% YoY). Sales on the other hand came in at Rs 8 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Sep 25, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - ELDER PHARMA COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS